the chugai competition in the ALK space is disturbing. Hopefully 113's apparently benign side effect profile will differentiate the two if Chugai's drug isn't well tolerated....a big if indeed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.